FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism

Bristol-Myers Squibb Company (BMS) and Pfizer Inc. have announced FDA has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE. It is estimated that every year, approximately 900,000 Americans are affected by DVT and PE.

“We are pleased that Eliquis is now available as an effective treatment option for DVT and PE,” said Douglas Manion, MD, Head of Specialty Development, BMS. “Eliquis offers oral dosing, no routine coagulation testing, and does not require the use of a parenteral anticoagulant or bridging during initiation.”

“DVT, which may lead to PE, can be a serious medical condition, with PE requiring immediate medical attention for treatment. Once a VTE has occurred, approximately 33 percent of patients are at risk of a recurrence within 10 years,” said Steve Romano, senior Vice President, Head of Medicines Development Group for Global Innovative Pharmaceuticals, Pfizer Inc. “The BMS and Pfizer alliance is committed to delivering important treatment options to patients and physicians.”